Liver-specific contrast agent-enhanced magnetic resonance and ¹⁸F-fluorodeoxyglucose positron emission tomography findings of hepatocellular adenoma: report of a case

Surg Today. 2012 Jan;42(2):200-4. doi: 10.1007/s00595-011-0067-7. Epub 2011 Dec 10.

Abstract

We report a case of hepatocellular adenoma, focusing on the findings of liver-specific contrast agent-enhanced magnetic resonance imaging (MRI) and ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG-PET). The patient was a 37-year-old woman, referred to us after contrast-enhanced computed tomography showed a homogeneous, poorly enhanced liver tumor, 2.8 cm in diameter. Magnetic resonance imaging showed a liver mass with significant fatty change. The tumor increased in size to 3.3 cm over 9 months of follow-up. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI revealed spotty enhancement in the hypointense tumor in the hepatobiliary phase. Subsequent FDG-PET showed increased uptake of FDG (maximum standardized uptake value 5.0), which suggested the possibility of malignancy. The patient underwent partial hepatectomy, and histological examination of the resected specimen revealed a tumor composed of hepatocyte-like cells with minimal cellular atypia and significant diffuse fatty change. Based on these findings, we diagnosed hepatocellular adenoma.

Publication types

  • Case Reports

MeSH terms

  • Adenoma, Liver Cell / diagnosis*
  • Adenoma, Liver Cell / surgery
  • Adult
  • Diagnosis, Differential
  • Female
  • Fluorodeoxyglucose F18*
  • Follow-Up Studies
  • Hepatectomy
  • Humans
  • Liver / diagnostic imaging
  • Liver / pathology
  • Liver Neoplasms / diagnosis*
  • Liver Neoplasms / surgery
  • Magnetic Resonance Imaging / methods*
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals*
  • Tomography, X-Ray Computed

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18